Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.

Maldarelli F.

Curr Opin HIV AIDS. 2011 Jan;6(1):49-56. doi: 10.1097/COH.0b013e32834134ea. Review.

PMID:
21228755
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Can HIV infection be eradicated through use of potent antiviral agents?

Josefsson L, Dahl V, Palmer S.

Curr Opin Infect Dis. 2010 Dec;23(6):628-32. doi: 10.1097/QCO.0b013e32833ff1d0. Review.

PMID:
20847693
4.

Reservoirs of HIV replication after successful combined antiretroviral treatment.

Belmonte L, Baré P, de Bracco MM, Ruibal-Ares BH.

Curr Med Chem. 2003 Feb;10(4):303-12. Review.

PMID:
12570703
5.

Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.

Hamer DH.

Curr HIV Res. 2004 Apr;2(2):99-111. Review.

PMID:
15078175
6.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
7.

Molecular mechanisms of HIV-1 proviral latency.

Bisgrove D, Lewinski M, Bushman F, Verdin E.

Expert Rev Anti Infect Ther. 2005 Oct;3(5):805-14. Review.

PMID:
16207172
8.
9.

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P.

AIDS. 2002 Jul 26;16(11):1479-87. Erratum in: AIDS 2002 Oct 18;16(15):2103.

PMID:
12131185
10.
11.

As good as it gets? The problem of HIV persistence despite antiretroviral drugs.

Sigal A, Baltimore D.

Cell Host Microbe. 2012 Aug 16;12(2):132-8. doi: 10.1016/j.chom.2012.07.005.

12.

Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication.

Pomerantz RJ.

Arch Immunol Ther Exp (Warsz). 2004 Sep-Oct;52(5):297-306. Review.

PMID:
15507870
13.

Attacking HIV provirus: therapeutic strategies to disrupt persistent infection.

Margolis DM, Archin NM.

Infect Disord Drug Targets. 2006 Dec;6(4):369-76. Review.

PMID:
17168802
14.

Prostratin as a new therapeutic agent targeting HIV viral reservoirs.

Hezareh M.

Drug News Perspect. 2005 Oct;18(8):496-500. Review.

PMID:
16391719
15.

Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.

Pérez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Muñoz-Fernandez MA, Moreno S, Castor TP, Calzado MA, Muñoz E.

Curr HIV Res. 2010 Sep;8(6):418-29.

PMID:
20636281
16.

Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs.

Sánchez-Duffhues G, Vo MQ, Pérez M, Calzado MA, Moreno S, Appendino G, Muñoz E.

Curr Drug Targets. 2011 Mar 1;12(3):348-56. Review.

PMID:
20955147
17.

Latency: the hidden HIV-1 challenge.

Marcello A.

Retrovirology. 2006 Jan 16;3:7. Review.

18.

HIV-1 latency and eradication of long-term viral reservoirs.

Coiras M, Lopez-Huertas MR, Alcami J.

Discov Med. 2010 Mar;9(46):185-91. Review.

19.
20.
Items per page

Supplemental Content

Support Center